Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Lasofoxifene (Estrogen Modulator) | Metastatic Estrogen Receptor-Positive Breast Cancer With ESR1 Mutations | Phase 3 | Dec 31, 2027 | Mgmt interest |
| Lasofoxifene (Estrogen Receptor Modulator) | ESR1-Mutated, ER-Positive, HER2-Negative Metastatic Breast Cancer | Phase 3 | Dec 31, 2027 | Mgmt interest |
Upcoming milestones
Company profile
Athira Pharma is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Metastatic Estrogen Receptor-Positive Breast Cancer With ESR1 Mutations
Data readoutESR1-Mutated, ER-Positive, HER2-Negative Metastatic Breast Cancer
Data readout